ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 98 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $248,390 | +21.1% | 51,748 | +89.5% | 0.00% | – |
| Q2 2023 | $205,031 | +78.6% | 27,301 | +7.5% | 0.00% | – |
| Q1 2023 | $114,830 | -95.0% | 25,405 | -87.5% | 0.00% | – |
| Q4 2022 | $2,288,643 | +974.5% | 203,074 | +814.5% | 0.00% | – |
| Q3 2022 | $213,000 | +56.6% | 22,206 | +31.6% | 0.00% | – |
| Q2 2022 | $136,000 | -86.3% | 16,874 | -71.2% | 0.00% | – |
| Q1 2022 | $992,000 | -33.4% | 58,681 | -15.4% | 0.00% | – |
| Q4 2021 | $1,490,000 | +192.7% | 69,325 | +903.8% | 0.00% | – |
| Q3 2021 | $509,000 | +57.6% | 6,906 | +16.9% | 0.00% | – |
| Q2 2021 | $323,000 | +38.6% | 5,907 | +86.0% | 0.00% | – |
| Q1 2021 | $233,000 | -62.0% | 3,175 | -55.3% | 0.00% | – |
| Q4 2020 | $613,000 | +91.0% | 7,110 | -16.5% | 0.00% | – |
| Q3 2020 | $321,000 | – | 8,510 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |